Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069638 | 0.91 | GHSR (0.36) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069720 | 0.90 | GHSR (0.36) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069534 | 0.83 | RIPK1 (0.34) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069793 | 0.82 | GHSR (0.39) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069733 | 0.82 | GHSR (0.35) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069537 | 0.81 | NOS3 (0.49) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069723 | 0.79 | GHSR (0.37) | GHSRRIPK1TACR1NOS3NOS1 | |
| SCHEMBL6070003 | 0.79 | TACR1 (0.34) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069767 | 0.75 | RIPK1 (0.34) | GHSRALDH1A1GAAL3MBTL1RIPK1 | |
| SCHEMBL6069203 | 0.74 | NOS3 (0.51) | GHSRALDH1A1GAAL3MBTL1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067667-B2 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-27 | — | — | US | disclosed |
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | JAROCH STEFAN (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127712-A1 | Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors | NOS3, NOS1, NOS2 | GHSR 4522/4885ALDH1A1 260/4885GAA 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.